# Emkay Your success is our success

# **Westlife Development**

Refer to important disclosures at the end of this report

# Demand trends encouraging; expect faster recovery

CMP
Rs 485
as of (June 28, 2021)

Target Price
Rs 630 (▲)

Rating BUY (■) Upside 29.9 %

FY23E

**4** 0

- Our interaction with management indicates strong traction in convenience channel sales, led by consumer shift to dominant brands & digital initiatives. Dine-in is currently impacted but faster recovery is expected vs. FY21 on easing restrictions and increasing vaccination.
- Expansion plans are intact at 25-30 store additions in FY22 despite second wave-led lockdowns. Ramp-up of Mc-Café network (present in 80% stores currently) and scale up of new products (fried chicken/gourmet burgers) ahead offer relatively better SSG outlook.
- WLDL was able to achieve pre-Covid margins in H2FY21 despite lower sales, driven by structural cost savings. It continues to work on further rental optimization and other cost efficiencies, and expects a much better margin profile upon full recovery.
- Faster recovery in dine-in can drive stronger SSG and margin gains for WLDL. With improving profitability and inexpensive valuations vs peers, the stock offers attractive upside potential. Maintain Buy with TP of Rs630 (32x Sept-23E pre-INDAS EV/EBITDA).

Strong traction in convenience channels to reduce lockdown impact: WLDL indicated stronger traction in the convenience channel, with 90%+ stores being operational (~290 stores vs. avg. ~200 stores in Q1FY21) despite the lockdown as consumers continued to opt for delivery from well-established brands. Convenience channel (50% sales contribution pre-Covid) was up 40% in Q4, with dine-in recovering to 90%. While the dine-in channel is impacted by restrictions in Q1, stronger sales growth in the convenience channel should result in a 60-70% sales recovery (vs. pre-Covid level), in our view. Own app sales are also gaining traction, with high-double digit contribution to digital sales (vs. low-single digit earlier). With ongoing vaccination, WLDL expects a quicker recovery led by faster dine-in recovery than the first unlock (75%/90% dine-in recovery in Q3/Q4FY21 post opening up in Oct'20).

**Expansion plans remain intact:** Management maintained its store addition target of 25-30 stores in FY22E, with plans to further scale up Mc-Café to the remaining network in next 2-3 years. Currently, Mc-Café is present in ~230 stores out of total 305 stores. Newly introduced products such as fried chicken in South India and gourmet burgers in Maharashtra are gaining traction and will be extended to the remaining network, driving higher unit sales.

Margin gains likely to continue post Q1: Rental contracts are being further optimized and some rebates are expected in Q1. Commentary remains positive on cost efficiencies, and WLDL hopes to see results from Q2 as sales normalise. Margin gains were impressive as it reached near pre-Covid margins in H2FY21 despite lower sales. Cost savings were broadbased, with employee & other occupancy costs falling ~30% in FY21 (vs. 35% sales decline).

**Attractive valuations vs. peers; maintain Buy:** We expect sales/EBITDA growth of 10%/20% in FY20-24, and faster recovery can drive upsides. Large penetration opportunity, improving profitability and valuations at discount to peers make it an attractive long-term bet. We value WLDL at 32x Sept-23E pre-INDAS EBITDA (vs. Jun-23E) with a TP of Rs630.

Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Goods & Retail (Page 7)

## Financial Snapshot (Consolidated)

(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	15,473	9,856	14,040	18,978	22,208
EBITDA	2,194	614	2,142	3,482	4,273
EBITDA Margin (%)	14.2	6.2	15.3	18.3	19.2
APAT	94	(1,036)	8	626	1,000
EPS (Rs)	0.6	(6.7)	0.0	4.0	6.4
EPS (% chg)	(36.4)	(1,208.0)	0.0	8,139.6	59.8
ROE (%)	1.6	(19.6)	0.2	12.2	16.8
P/E (x)	807.3	(72.9)	9,944.1	120.7	75.5
EV/EBITDA (x)	38.1	135.3	39.0	23.7	19.0
P/BV (x)	13.1	15.7	15.7	13.9	11.7

Source: Company, Emkay Research

Change in Estimates	
EPS Chg FY22E/FY23E (%)	-/
Target Price change (%)	5
Target Period (Months)	12
Previous Reco	BUY
Emkov vo Concensus	

### Emkay vs Consensus

**Emkay** 

EPS	Estim	ates
-----	-------	------

FY22E

Ellikay	-	4.0
Consensus	0.3	5.0
Mean Consensus TP (12M)		Rs 504
Stock Details		
Bloomberg Code		WLDL IN
Face Value (Rs)		2
Shares outstanding (mn)		156
52 Week H/L		553 / 300
M Cap (Rs bn/USD bn)		76 / 1.02
Daily Avg Volume (nos.)		2,44,144
Daily Avg Turnover (US\$ mi	า)	1.5

Chaua	سالمامط	Dattava	NA~~ 124
Smare	holding	Pauern	IVIAL ZI

Promoters	58.0%
FIIs	10.8%
DIIs	20.8%
Public and Others	10.4%

# Price Performance (%) 1M 3M 6M 12M Absolute 1 7 13 52 Rel. to Nifty (1) (2) (1)

## Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

## Ashit Desai

ashit.desai@emkayglobal.com


+91 22 6612 1340

## Devanshu Bansal

devanshu.bansal@emkayglobal.com +91 22 6612 1385


## **Story in Charts**

Exhibit 1: Convenience channel continues to see strong traction with further improvement vs. Q4




Source: Company, Emkay Research

Exhibit 3: SSG recovery vs. peers is impressive over the last few quarters




Source: Company, Emkay Research

Exhibit 5: Mc-café addition to stores continues at a healthy pace




Source: Emkay Research, Company, \*Pre-IndAS116 margins

Exhibit 7: Cost savings have been broad-based across all cost lines




Source: Emkay Research, Company, \*Pre-IndAS116 margins

Exhibit 2: Overall sales recovery in FY21; expect recovery in FY22 to be faster with ongoing vaccination




Source: Company, Emkay Research

Exhibit 4: Lesser impact of second lockdown, largely 90%+ stores operational




Source: Company, Emkay Research

Exhibit 6: Margins recovered despite lower sales and weaker mix




Source: Emkay Research, Company

Exhibit 8: Margin should be much better on full recovery of unit sales



Source: Emkay Research, Company

## Exhibit 9: WLDL 2-yr forward EV/EBITDA chart



Source: Emkay Research, Company

**Exhibit 10: Key assumptions** 

	FY19	FY20	FY21	FY22E	FY23E	FY24E
SSG (%)	17.2	4.0	-39.0	42.0	27.0	10.0
Store Addition (No.)	19	23	-15	30	32	32
Gross Margins (%)	64.1	65.6	64.0	65.5	67.0	67.5
EBITDA Margins (%, post IndAS116)		14.3	6.3	15.4	18.4	19.3

Source: Company, Emkay Research

## **Key Financials (Consolidated)**

## **Income Statement**

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	15,473	9,856	14,040	18,978	22,208
Expenditure	13,279	9,242	11,898	15,496	17,935
EBITDA	2,194	614	2,142	3,482	4,273
Depreciation	1,442	1,546	1,538	1,855	2,061
EBIT	753	(931)	603	1,626	2,212
Other Income	135	447	150	150	173
Interest expenses	808	845	743	936	1,043
PBT	79	(1,329)	10	840	1,342
Tax	(14)	(293)	3	214	342
Extraordinary Items	(166)	42	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	(73)	(994)	8	626	1,000
Adjusted PAT	94	(1,036)	8	626	1,000

## **Balance Sheet**

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	311	311	311	311	311
Reserves & surplus	5,459	4,501	4,508	5,134	6,134
Net worth	5,770	4,812	4,819	5,445	6,445
Minority Interest	0	0	0	0	0
Loan Funds	9,659	9,680	9,922	10,091	10,492
Net deferred tax liability	(214)	(214)	(214)	(214)	(214)
Total Liabilities	15,216	14,278	14,528	15,323	16,723
Net block	14,080	12,843	13,134	13,181	13,086
Investment	1,935	2,348	2,348	2,348	2,348
Current Assets	1,176	1,606	963	2,201	4,048
Cash & bank balance	30	110	(33)	971	2,621
Other Current Assets	223	100	115	132	152
<b>Current liabilities &amp; Provision</b>	2,201	2,744	2,143	2,633	2,984
Net current assets	(1,025)	(1,138)	(1,180)	(432)	1,064
Misc. exp	0	0	0	0	0
Total Assets	15,216	14,278	14,528	15,323	16,723

## **Cash Flow**

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
PBT (Ex-Other income) (NI+Dep)	(222)	(1,735)	(140)	690	1,169
Other Non-Cash items	0	0	0	0	0
Chg in working cap	124	194	(101)	255	155
Operating Cashflow	2,015	1,143	2,039	3,522	4,086
Capital expenditure	(1,285)	(485)	(1,130)	(1,202)	(1,266)
Free Cash Flow	730	658	909	2,320	2,820
Investments	469	(414)	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(681)	(451)	(980)	(1,052)	(1,094)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(502)	315	(315)	(500)	(300)
Dividend paid (incl tax)	0	0	0	0	0
Other Financing Cash Flow	(746)	(756)	(742)	(840)	(947)
Financing Cashflow	(1,396)	(611)	(1,201)	(1,467)	(1,342)
Net chg in cash	(62)	80	(143)	1,003	1,651
Opening cash position	92	30	110	(33)	971
Closing cash position	30	110	(33)	971	2,621

Source: Company, Emkay Research

## **Key Ratios**

Profitability (%)	FY20	FY21	FY22E	FY23E	FY24E
EBITDA Margin	14.2	6.2	15.3	18.3	19.2
EBIT Margin	4.9	(9.5)	4.3	8.6	10.0
Effective Tax Rate	(18.0)	22.0	25.5	25.5	25.5
Net Margin	0.6	(10.5)	0.1	3.3	4.5
ROCE	7.6	(3.3)	5.2	11.9	14.9
ROE	1.6	(19.6)	0.2	12.2	16.8
RoIC	8.3	(7.6)	5.1	13.7	19.0

Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	0.6	(6.7)	0.0	4.0	6.4
CEPS	9.9	3.3	9.9	15.9	19.7
BVPS	37.1	30.9	31.0	35.0	41.4
DPS	0.0	0.0	0.0	0.0	0.0

Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	807.3	(72.9)	9,944.1	120.7	75.5
P/CEPS	42.6	128.2	42.2	26.3	21.3
P/BV	13.1	15.7	15.7	13.9	11.7
EV / Sales	5.4	8.5	6.0	4.4	3.7
EV / EBITDA	38.1	135.3	39.0	23.7	19.0
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0

Gearing Ratio (x)	FY20	FY21	FY22E	FY23E	FY24E
Net Debt/ Equity	1.4	1.6	1.7	1.3	0.9
Net Debt/EBIDTA	3.7	12.3	3.7	2.0	1.4
Working Cap Cycle (days)	(24.9)	(46.2)	(29.8)	(27.0)	(25.6)

Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	10.4	(36.3)	42.4	35.2	17.0
EBITDA	85.1	(72.0)	248.6	62.6	22.7
EBIT	133.4	(223.8)	0.0	169.5	36.0
PAT	(149.5)	0.0	0.0	8,139.6	59.8

Quarterly (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
Revenue	3,364	939	2,095	3,251	3,576
EBITDA	379	(422)	42	501	499
EBITDA Margin (%)	11.3	(45.0)	2.0	15.4	14.0
PAT	(253)	(605)	(325)	1	(65)
EPS (Rs)	(1.6)	(3.9)	(2.1)	-	(0.4)

Source: Company, Emkay Research

Shareholding Pattern (%)	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21
Promoters	59.1	59.1	59.1	59.1	58.0
FIIs	12.7	10.1	10.0	9.6	10.8
DIIs	16.1	18.6	19.4	20.5	20.8
Public and Others	12.2	12.2	11.5	10.9	10.4


Source: Capitaline

## RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
14-May-21	428	600	12m	Buy	Ashit Desai
17-Mar-21	508	600	12m	Buy	Ashit Desai

Source: Company, Emkay Research

## RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

## Analyst: Ashit Desai

## **Contact Details**

ashit.desai@emkayglobal.com +91 22 6612 1340

### Sector

Consumer Goods & Retail

## Analyst bio

Ashit Desai holds a PGDM and FRM (US GARP) with 13 years of research experience on the sell side. His team currently covers 24 stocks in the Indian Consumer and Retail space.

## Emkay Alpha Portfolio - Consumer Goods & Retail

**EAP** sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Consumer Goods & Retail	10.52	10.52	0%	0	100.00
Asian Paints	1.50	0.62	-59%	-88	5.89
Berger Paints	0.22	0.00	-100%	-22	0.00
Britannia Industries	0.48	0.52	9%	4	4.95
Colgate-Palmolive	0.25	0.30	20%	5	2.81
Dabur India	0.35	0.33	-7%	-3	3.11
Emami	0.13	0.16	24%	3	1.50
Godrej Consumer Products	0.36	0.32	-12%	-4	3.04
Hindustan Unilever	2.42	2.04	-16%	-38	19.35
ITC	1.98	2.04	3%	6	19.36
Marico	0.29	0.31	6%	2	2.94
Nestle India	0.69	0.57	-17%	-12	5.42
Pidilite Industries	0.36	0.00	-100%	-36	0.00
Radico Khaitan	0.00	0.39	NA	39	3.67
United Breweries	0.10	0.51	384%	40	4.83
United Spirits	0.00	0.36	NA	36	3.43
Varun Beverages	0.11	0.10	-10%	-1	0.96
ABFRL	0.07	0.17	134%	10	1.66
Jubilant FoodWorks	0.21	0.25	15%	3	2.34
Page Industries	0.19	0.21	13%	2	1.99
Shoppers Stop	0.00	0.00	NA	0	0.00
Titan Company	0.81	1.08	34%	27	10.29
Westlife Development	0.00	0.26	NA	26	2.45
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

## Sector portfolio NAV

	Base					Latest
	1-Apr-19	25-Jun-20	24-Dec-20	25-Mar-21	26-May-21	25-Jun-21
EAP - Consumer Goods & Retail	100.0	104.4	119.6	117.6	125.5	130.4
BSE200 Neutral Weighted Portfolio (ETF)	100.0	98.2	116.3	112.1	121.1	124.3


<sup>\*</sup>Performance measurement base date 1<sup>st</sup> April 2019 Source: Emkay Research

## Price Performance (%)

	1m	3m	6m	12m
EAP - Consumer Goods & Retail	3.9%	10.9%	9.1%	24.9%
BSE200 Neutral Weighted Portfolio (ETF)	2.6%	10.9%	6.8%	26.6%

Source: Emkay Research

## **NAV** chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

<sup>\*</sup> Not under coverage: Equal Weight

<sup>■</sup> High Conviction/Strong Over Weight

## **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Completed Date: 29 Jun 2021 01:24:19 (SGT) Dissemination Date: 29 Jun 2021 01:25:19 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayqlobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of June 28, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of June 28, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 28, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the June 28, 2021

<sup>&</sup>lt;sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## **RESTRICTIONS ON DISTRIBUTION**

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
United Kingdom	In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

## Emkay Global Financial Services Ltd.

**CIN -** L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com